Real-World HCM drug use under the microscope
NCT ID NCT06372457
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 331 adults with hypertrophic cardiomyopathy (HCM) to see how they are treated in everyday medical practice, especially with the drug mavacamten. Researchers will collect data on diagnosis, symptoms, treatments, and outcomes over time. The goal is to understand real-world patterns and improve care for HCM patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mavacamten
- What this could lead to
- If successful, this study could reveal how well mavacamten works in real-world settings and help doctors better manage HCM.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by factors like patient selection or incomplete data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY (HCM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IQVIA
Durham, North Carolina, 27703, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart scan AI could predict sudden cardiac death risk in common heart condition
- Experimental pill aims to ease thick heart muscle symptoms
- Massive HCM database aims to unlock better heart care
- Heart drug swap tested for safer symptom control
- Heart drug mavacamten shows promise in Real-World study
- Can a new heart drug improve blood flow in thick heart muscle?